PRGO

EX-99.1

2 cy26q1ex991pressrelease.htm

EX-99.1

Document

EXHIBIT 99.1

Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations

•Mitigating category headwinds with market share gains through implementation of Three‑S plan.

•Specialty Care segment achieved net sales and segment operating income growth, led by continued momentum in Compeed®, Opill®, and ellaOne® brands.

•Completed divestiture of Dermacosmetics business after quarter end; upfront proceeds of approximately €306 million will support debt reduction.

•Maintained full‑year 2026 outlook with continued expectation for second half improvement.

DUBLIN, May 6, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced financial results from continuing operations for the first quarter ended March 28, 2026.

"Our first quarter results reflect tangible progress as we continue to transform Perrigo into a more focused, disciplined, and consistent business," said President and CEO Patrick Lockwood-Taylor. "Despite a challenging operating environment, we are advancing a clear plan to address the factors within our control. Our Three‑S plan and shift to a category‑led operating model are strengthening execution and accountability, and the momentum we are seeing in areas such as U.S. Store Brand and Women’s Health are encouraging. We also continue to simplify and streamline the organization through disciplined portfolio actions, including the sale of our Dermacosmetics business, with proceeds expected to be used to support debt reduction.

“We are maintaining our full‑year guidance, supported by clear, quantifiable factors expected to drive improvement in the second half of the year. We recognize that the environment is dynamic, and we are monitoring potential impacts related to geopolitical developments in the Middle East and retailer inventory destocking. Against this backdrop, we are well-positioned to deliver on our 2026 outlook while building a foundation for long-term growth.”

1

First Quarter Results

As announced last quarter, the Company now reports results on both an All In and Core Perrigo basis. All In results reflect the entirety of our business, while Core represents our go-forward business and excludes Infant Formula and previously announced divestitures.

All In Core

1Q'261Q'25Change 1Q'261Q'25Change

Reported Net Sales $969$1,044(7.2)%$842$918(8.3)%

Reported Gross Margin 33.6%37.6%(400)bps

Reported Operating Margin (38.4)%4.5%n/m

Reported Diluted Earnings Per Share ("EPS")$(2.81)$0.00n/m

All InCore

1Q'261Q'25Change1Q'261Q'25Change

Organic Net Sales(1) $939$1,042(9.9)%$817$918(11.0)%

Adj. Gross Margin 37.6%41.0%(340)bps39.2%40.8%(160)bps

Adj. Operating Margin11.6%14.0%(240)bps12.8%13.9%(110)bps

Adj. Diluted EPS$0.43$0.60(28.3)%$0.40$0.50(20.0)%

(1) See attached Appendix for details. Change in net sales on an organic basis excludes the effects of acquisitions, divestitures and exited products, and the impact of currency.

(2) Share gains according to Circana 13-weeks ending 03/29/26 vs. prior year period in the categories where Perrigo participates in cough cold, allergy, digestive health, pain, nicotine replacement, skin care, and women’s health.

(3) All tables and data may not add due to rounding. Percentages are based on actuals.

Net Sales

•Core net sales were $842 million, declining 8.3% year over year, while Core organic net sales decreased 11.0%. Core organic results primarily reflect lower consumption across both the U.S. and Europe. Reduced consumption was driven in part by lower seasonal incidence of cough and cold versus the prior year, which was an approximately 3.5% net sales headwind, and also led to lower retailer inventory levels, creating an additional net sales headwind of approximately 3.0%. These factors were partially offset by continued market share gains, supported by innovation launches and performance of Women’s Health products. Core organic net sales comprised net pricing of 0.2% and volume/mix of -11.0%.

•All In reported net sales declined 7.2% year over year to $969 million. The decrease was driven by the same factors impacting Core net sales, partially offset by Infant Formula net sales growth.

Gross Margin

•Reported gross margin was 33.6%, a decrease of 400 basis points versus the prior year due to the impact of prior-year manufacturing volume headwinds in Infant Formula and U.S. OTC, and lower net sales volumes, primarily within our Self Care reporting segment, partially offset by the net recognition of a recovery of a portion of previously paid tariffs of approximately $21 million.

•Core adjusted gross margin decreased 160 basis points to 39.2% driven by lower net sales volumes, the carryover impact of prior-year manufacturing volume headwinds in U.S. OTC, and unfavorable mix. These factors were partially offset by the net recognition of a recovery of a portion of previously paid

EX-99.1

2 exhibit991historicalrecast.htm

EX-99.1

Document

Exhibit 99.1

PERRIGO COMPANY PLC

SELECT SEGMENT INFORMATION

QUARTERS AND FISCAL YEARS TO DATE 2025 and 2024

(in millions)

(unaudited)

Three Months EndedTwelve Months Ended

March 29, 2025June 28, 2025September 27, 2025December 31, 2025December 31, 2025

Net Sales

Self Care $614.3 $598.6 $633.1 $687.6 $2,533.5

Specialty Care 199.1 233.1 191.2 176.0 799.3

Infant Formula 87.8 82.0 89.3 99.9 359.0

Total Segments Net Sales $901.2 $913.6 $913.6 $963.4 $3,691.8

All Other 142.7 142.7 129.7 146.2 561.3

Consolidated Net Sales $1,043.9 $1,056.3 $1,043.3 $1,109.6 $4,253.1

Three Months EndedTwelve Months Ended

Net Sales March 30, 2024June 29, 2024September 28, 2024December 31, 2024December 31, 2024

Self Care $627.7 $600.5 $637.6 $688.6 $2,554.3

Specialty Care 208.7 220.2 188.3 179.5 796.6

Infant Formula 74.3 74.9 115.4 132.4 397.0

Total Segments Net Sales $910.7 $895.6 $941.3 $1,000.4 $3,747.9

All Other 171.5 170.0 146.3 137.8 625.6

Consolidated Net Sales $1,082.1 $1,065.5 $1,087.5 $1,138.3 $4,373.4

Note: Amounts may not add or recalculate due to rounding.

Exhibit 99.1

PERRIGO COMPANY PLC

SELECT SEGMENT INFORMATION

QUARTERS AND CALENDAR YEAR TO DATE 2025

(in millions)

(unaudited)

Three Months Ended Twelve Months Ended

Continuing Operations March 29, 2025June 28, 2025September 27, 2025December 31, 2025December 31, 2025

Segment adjusted operating income:

Self Care $112.8 $93.8 $130.6 $135.3 $472.6

Specialty Care 42.1 66.3 42.1 50.0 200.5

Infant Formula 10.6 (12.2)14.6 (3.4)9.6

Total segment adjusted operating income$165.5 $147.9 $187.3 $181.9 $682.6

All Other21.0 25.7 22.5 24.2 93.4

Unallocated (39.9)(38.5)(36.4)(38.9)(153.7)

Consolidated adjusted operating income $146.6 $135.2 $173.4 $167.2 $622.3

Note: Amounts may not add or recalculate due to rounding.

Exhibit 99.1

PERRIGO COMPANY PLC

RECONCILIATION OF NON-GAAP MEASURES

SELECT CONSOLIDATED INFORMATION

QUARTERS AND CALENDAR YEAR TO DATE 2025

(in millions)

(unaudited)

Three Months Ended Twelve Months Ended

Consolidated Continuing OperationsMarch 29, 2025June 28, 2025September 27, 2025December 31, 2025December 31, 2025

Reported Operating Income (Loss) $46.9 $45.4 $72.6 $(1,287.2)$(1,122.2)

Pre-tax adjustments:

Amortization expense related primarily to acquired intangible assets 55.0 56.8 56.0 55.7 223.5

Unusual litigation8.9 15.4 15.0 19.7 59.0

Restructuring charges and other termination benefits 29.4 8.7 20.9 13.0 71.9

Impairment charges (1) 3.1 1.5 — 1,358.5 1,363.1

Infant formula remediation0.9 — — — 0.9

Other(2) 2.4 7.4 8.9 7.4 26.1

Consolidated adjusted operating income $146.6 $135.2 $173.4 $167.2 $622.3

Note: Amounts may not add or recalculate due to rounding.

(1) During the three months ended March 29, 2025, we determined the carrying value of the Richard Bittner Business net assets held for sale exceeded their fair value less costs to sell, resulting in a total impairment charge of $3.1 million, inclusive of a goodwill impairment charge of $1.2 million. During the three months ended June 28, 2025, we determined the carrying value of our Prevacid® branded product was impaired by $1.5 million. During the three months ended December 31, 2025, we determined the carrying value of our reporting units exceeded their estimated fair value and recorded a goodwill impairment charge of $1.3 billion and the existence of an other-than-temporary impairment of our equity method investment in Kazmira LLC and recorded an impairment charge of $33.6 million.

(2) Other pre-tax adjustments for the three months ended March 29, 2025 are related to professional consulting fees for potential divestiture activity. Other pre-tax adjustments for the three months ended June 28, 2025 are primarily related to $4.5 million of accelerated depreciation as a result of our Nutrition Network Optimization Project and $2.8 million of professional consulting fees for divestiture activity. Other pre-tax adjustments for the three months ended September 27, 2025 includes $4.2 million of accelerated depreciation and a $1.6 million asset abandonment related to our Nutrition Network Optimization Project and $3.1 million of professional consulting fees for divestiture activity. Other pre-tax adjustments for the three months ended December 31, 2025 includes $3.8 million of professional consulting fees for potential divestiture activity and $3.2 million of accelerated depreciation.

prgo-202602260001585364false00015853642026-02-262026-02-260001585364prgo:OrdinaryShares0001ParValueMember2026-02-262026-02-260001585364prgo:A4.900SeniorNotesDueJune152030Member2026-02-262026-02-260001585364prgo:A6.125SeniorNotesDue2032Member2026-02-262026-02-260001585364prgo:A5.375SeniorNotesDue2032Member2026-02-262026-02-260001585364prgo:A5.30UnsecuredSeniorNotesDueNovember152043Member2026-02-262026-02-260001585364prgo:A49SeniorLoanDue2024Member2026-02-262026-02-26

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 26, 2026

Perrigo Company plc

(Exact name of registrant as specified in its charter)

Commission file number 001-36353

Ireland Not Applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

The Sharp Building, Hogan Place, Dublin 2, Ireland D02 TY74 +353 1 7094000

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Not Applicable (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act

(17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐         Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered

Ordinary shares, €0.001 par valuePRGONew York Stock Exchange 4.900% Notes due 2030 PRGO30New York Stock Exchange 6.125% Notes due 2032

PRGO32A

New York Stock Exchange 5.375% Notes due 2032

PRGO32B

New York Stock Exchange 5.300% Notes due 2043PRGO43New York Stock Exchange 4.900% Notes due 2044PRGO44New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 2.02.    Results of Operations and Financial Condition

On February 26, 2026, Perrigo Company plc (the “Company”) released earnings for the fourth quarter ended December 31, 2025. The press release related to the Company’s earnings is attached as Exhibit 99.1.

The Company provides non-GAAP financial measures as additional information that it believes is useful to investors and analysts in evaluating the performance of the Company's ongoing operating trends, facilitating comparability between periods and, where applicable, with companies in similar industries and assessing the Company's prospects for future performance. These non-GAAP financial measures exclude items, such as amortization expense, unusual litigation, impairment charges, restructuring charges, and acquisition and integration-related charges, that by their nature affect comparability of operational performance or that we believe obscure underlying business operational trends. The intangible asset amortization excluded from these non-GAAP financial measures represents the entire amount recorded within the Company’s GAAP financial statements and is excluded because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised. The revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. The non-GAAP measures the Company provides are consistent with how management analyzes and assesses the operating performance of the Company, and disclosing them provides investor insight into management’s view of the business. Management uses these adjusted financial measures for planning and forecasting in future periods, and evaluating segment and overall operating performance. In addition, management uses certain of the profit measures as factors in determining compensation.

Non-GAAP measures re